PDGFRB and non-small cell lung carcinoma: Anlotinib is a multi-target drug approved for the third line treatment of advanced NSCLC, which could inhibit the vascular endothelial growth factor (VEGFR) 1-3, platelet-derived growth factor (PDGFR) α, PDGFRβ, C-proto-oncogenic receptor tyrosine kinase (C-KIT) and RET.